[go: up one dir, main page]

MA35097B1 - Composition vaginale à base d'alkylpolyglucosides - Google Patents

Composition vaginale à base d'alkylpolyglucosides

Info

Publication number
MA35097B1
MA35097B1 MA36359A MA36359A MA35097B1 MA 35097 B1 MA35097 B1 MA 35097B1 MA 36359 A MA36359 A MA 36359A MA 36359 A MA36359 A MA 36359A MA 35097 B1 MA35097 B1 MA 35097B1
Authority
MA
Morocco
Prior art keywords
alkylpolyglucosides
composition based
vaginal composition
vaginal
alkylpolyglycosides
Prior art date
Application number
MA36359A
Other languages
English (en)
Inventor
Luca Ivan Ardolino
Giuseppe Brugali
Original Assignee
Effik S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT000715A external-priority patent/ITMI20110715A1/it
Priority claimed from IT000716A external-priority patent/ITMI20110716A1/it
Priority claimed from IT000717A external-priority patent/ITMI20110717A1/it
Application filed by Effik S A filed Critical Effik S A
Publication of MA35097B1 publication Critical patent/MA35097B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention porte sur une composition vaginale à base d'alkylpolyglycosides, en particulier pour le traitement d'infections à
MA36359A 2011-04-29 2013-10-24 Composition vaginale à base d'alkylpolyglucosides MA35097B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IT000715A ITMI20110715A1 (it) 2011-04-29 2011-04-29 Composizione vaginale a base di alchilpoliglicosidi
IT000716A ITMI20110716A1 (it) 2011-04-29 2011-04-29 Composizione vaginale a base di alchilpoliglicosidi
IT000717A ITMI20110717A1 (it) 2011-04-29 2011-04-29 Composizione vaginale a base di alchilpoliglicosidi
PCT/IB2012/052119 WO2012147056A1 (fr) 2011-04-29 2012-04-27 Composition vaginale à base d'alkylpolyglucosides

Publications (1)

Publication Number Publication Date
MA35097B1 true MA35097B1 (fr) 2014-05-02

Family

ID=46197625

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36359A MA35097B1 (fr) 2011-04-29 2013-10-24 Composition vaginale à base d'alkylpolyglucosides

Country Status (15)

Country Link
US (1) US20140051650A1 (fr)
EP (1) EP2643003B1 (fr)
JP (1) JP2014512408A (fr)
KR (1) KR20140041493A (fr)
CN (1) CN103561749A (fr)
BR (1) BR112013027221A2 (fr)
CA (1) CA2819632C (fr)
ES (1) ES2532884T3 (fr)
MA (1) MA35097B1 (fr)
MX (1) MX363417B (fr)
PL (1) PL2643003T3 (fr)
PT (1) PT2643003E (fr)
RU (1) RU2013153087A (fr)
WO (1) WO2012147056A1 (fr)
ZA (1) ZA201307807B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018013583A2 (fr) * 2016-07-11 2018-01-18 The Brigham And Women's Hospital, Inc. Cocktail de lactobacillus vaginal médicinal
EP3664794A4 (fr) * 2017-08-11 2021-01-06 Natureza, Inc. Dérivés de l'acide laurique présentant une activité inhibitrice contre des organismes à gram positif et/ou à gram négatif
CN111759852A (zh) * 2020-08-04 2020-10-13 驯鹿(北京)管理咨询有限公司 一种阴道用药物组合物及其药物制剂、制备方法和用途
WO2024262189A1 (fr) * 2023-06-20 2024-12-26 東洋精糖株式会社 Agent permettant de supprimer la prolifération de bactéries, produit cosmétique, quasi-médicament et composition pharmaceutique contenant ledit agent et procédé permettant de supprimer la prolifération de bactéries
CN117535208B (zh) * 2024-01-04 2024-03-29 四川厌氧生物科技有限责任公司 一种卷曲乳杆菌及其在女性生殖道健康中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE500777C2 (sv) * 1992-04-14 1994-08-29 Hydro Pharma Ab Antimikrobiell komposition med potentierad effekt innehållande bl a vissa monoglycerider, förfarande för framställning därav samt användning därav
US20020165168A1 (en) * 1995-12-16 2002-11-07 Joachim Bunger Use of sugar derivatives as antimicrobial, antimycotic and/or antiviral active substances
FR2748937B1 (fr) * 1996-05-24 1998-07-31 Ulice Sa Utilisation d'alpha-alklyglucosides et d'esters d'alpha-alkylglucosides en tant qu'agents emulsionnants anti-microbiens
AUPO690997A0 (en) * 1997-05-20 1997-06-12 Novapharm Research (Australia) Pty Ltd Alkylpolyglucosides containing disinfectant compositions active against pseudomonas microorganism
US6599521B1 (en) * 2000-11-28 2003-07-29 Kimberly-Clark Worldwide, Inc. Absorbent articles for the inhibition of exoprotein production from Gram positive bacteria
US6531435B1 (en) * 2000-11-28 2003-03-11 Kimberly-Clark Worldwide, Inc. Compositions for the inhibition of exoprotein production from Gram positive bacteria
US6534548B1 (en) * 2001-10-02 2003-03-18 Kimberly-Clark Worldwide, Inc. Isoprenoid compositions for the inhibition of exoprotein production from gram positive bacteria
JP3993163B2 (ja) * 2003-12-12 2007-10-17 花王株式会社 抗菌剤及び抗菌液体洗浄剤組成物
DE102004031668A1 (de) * 2004-06-25 2006-02-09 Beiersdorf Ag Produkte zur Reinigung der Intimregion
FR2875240B1 (fr) * 2004-09-16 2006-11-17 Biomerieux Sa Procede de detection de streptococcus agalactiae en utilisant l'activite alpha-glucosidase
US20060223765A1 (en) * 2005-03-30 2006-10-05 Kimberly-Clark Worldwide, Inc. Method for inhibiting and/or treating vaginal infection
US7786176B2 (en) * 2005-07-29 2010-08-31 Kimberly-Clark Worldwide, Inc. Vaginal treatment composition containing xylitol
WO2010010345A2 (fr) * 2008-07-22 2010-01-28 Polybiotech Limited Compositions désinfectantes et procédés associés
JP2010265189A (ja) * 2009-05-13 2010-11-25 Nippon Fine Chem Co Ltd 抗菌性化粧料

Also Published As

Publication number Publication date
WO2012147056A1 (fr) 2012-11-01
ES2532884T3 (es) 2015-04-01
CA2819632A1 (fr) 2012-11-01
MX363417B (es) 2019-03-22
BR112013027221A2 (pt) 2016-12-27
ZA201307807B (en) 2015-01-28
PT2643003E (pt) 2015-03-09
CA2819632C (fr) 2018-01-02
KR20140041493A (ko) 2014-04-04
US20140051650A1 (en) 2014-02-20
CN103561749A (zh) 2014-02-05
JP2014512408A (ja) 2014-05-22
PL2643003T3 (pl) 2015-07-31
EP2643003B1 (fr) 2014-12-17
MX2013012557A (es) 2014-03-27
EP2643003A1 (fr) 2013-10-02
RU2013153087A (ru) 2015-06-10

Similar Documents

Publication Publication Date Title
ITMI20110316A1 (it) Composizione effervescente in forma solida per uso in applicazioni vaginali per il trattamento di infezioni vaginali.
EP2838524A4 (fr) Compositions pour le traitement topique d'infections microbiennes
MA33244B1 (fr) Composes de vinylindazolyle
CL2017002283A1 (es) Formulaciones de anticuerpos y métodos (divisional de solicitud n°1081-2014)
SMT201500148B (it) Composizioni per uso nel trattamento di infezioni virali
JP2013531018A5 (fr)
DOP2010000326A (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
MA35097B1 (fr) Composition vaginale à base d'alkylpolyglucosides
FR2975600B1 (fr) Agents pour le traitement de tumeurs
RS53893B1 (en) USE OF BIOTIN FOR MULTIPLE SCLEROSIS TREATMENT
EP2828100A4 (fr) Traitement de surface pour une surface d'implant
FR2954938B1 (fr) Composition d'email pour vitroceramique
EP2773774A4 (fr) Biomarqueurs pour le traitement de tslp
EP2786738A4 (fr) Composition d'agent de traitement des cheveux
MX2012007332A (es) Agonistas de mglu2.
SMT201500086B (it) Uso del nifuratel per il trattamento di infezioni causate dalla specie atopobium
GEP201606595B (en) (r) -nifuratel, its use for the treatment of infections and synthesis of (r) and (s) –nifuratel
IN2015DN00515A (fr)
MA34827B1 (fr) Protéine hybrides robo1-fc à utiliser dans traitement d'hépatocarcinomes
EP2427438A4 (fr) Pyrimidine-2,4,6-triones destinée à être utilisée pour le traitement d'une sclérose latérale amyotrophe
BR112015016033A2 (pt) composições e métodos para tratamento de infecções por bactérias
EA201200017A1 (ru) Новая кристаллическая форма пемироласта
EP2578215A4 (fr) Utilisation d'oxaloacétate pour le traitement de l'ischémie
FR2990859B1 (fr) Utilisation d'une molecule h4 agoniste pour le traitement de la mucoviscidose
EP2753626A4 (fr) Conjugués llp2a-bisphosphonate pour le traitement de l'ostéoporose